Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 3(63), 2019

DOI: 10.1128/aac.01722-18

Links

Tools

Export citation

Search in Google Scholar

In Vitro and In Vivo Studies of Spironolactone as an Antischistosomal Drug Capable of Clinical Repurposing

Journal article published in 2018 by Rafael A. Guerra, Marcos P. Silva, Tais C. Silva, Maria C. Salvadori ORCID, Fernanda S. Teixeira ORCID, Rosimeire N. de Oliveira, Jefferson A. Rocha, Pedro L. S. Pinto, Josué de Moraes
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Schistosomiasis is a parasitic flatworm disease that infects over 200 million people worldwide, especially in poor communities. Treatment and control of the disease rely on just one drug, praziquantel.